Form 4: Bicara Therapeutics COO Sells Shares

Bicara Therapeutics President and COO Ryan Cohlhepp executed pre-planned sales of 12,500 common shares following the exercise of stock options.

Summary

• Ryan Cohlhepp, President and COO, and a Director of Bicara Therapeutics Inc. (BCAX), exercised options to acquire 8,000 shares of common stock at an exercise price of $3.7898 per share.
• Concurrently, Cohlhepp sold a total of 12,500 shares of common stock in two separate transactions.
• The first sale involved 8,000 shares at a weighted average price of $19.6571 per share.
• The second sale involved 4,500 shares at a weighted average price of $19.6571 per share.
• These transactions were executed on March 16, 2026, under a Rule 10b5-1 trading plan adopted on February 12, 2025.
• Following these transactions, Cohlhepp beneficially owns 200,641 shares of common stock and 117,334 stock options.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. While insider selling can sometimes be a negative signal, the execution under a Rule 10b5-1 plan mitigates concerns, suggesting a pre-planned liquidity event rather than a reaction to new company-specific information.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, indicating a planned liquidity event rather than a reaction to new negative information.
• The sale price of approximately $19.66 per share is significantly higher than the option exercise price of $3.79, indicating a profitable transaction for the insider.

Negatives

• Insider selling, even if pre-planned, can sometimes be perceived by the market as a lack of confidence, though the 10b5-1 plan mitigates this.

Industry Context

StockSavvy.ai notes that insider transactions, particularly those executed under Rule 10b5-1 plans, are common in the biotechnology sector as executives monetize vested equity compensation. While a sale, the pre-planned nature typically reduces concerns about immediate negative sentiment compared to unplanned sales.

Stakeholder Impact

• Shareholders may observe the insider selling, but the 10b5-1 plan context should temper any negative interpretations regarding management's confidence.

Key Dates

Recommendation

This Form 4 filing details a routine, pre-planned insider transaction under a Rule 10b5-1 plan, where the President and COO exercised options and sold a portion of the resulting shares. Such transactions are typically for personal financial planning and do not inherently signal a change in the company's fundamental outlook. Therefore, it does not provide sufficient new information to warrant a change from a 'hold' recommendation based solely on this filing.

Keywords

Bicara Therapeutics, BCAX, Ryan Cohlhepp, Insider Trading, Form 4, Stock Option Exercise, Share Sale, 10b5-1 Plan, Biotechnology, Executive Compensation